Home> Trial Details

Information Clinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.Learn why

Optimise reading forHealth Professionals Patients

RecruitingLast updated:15 August 2023

PORCUPINE2: This Phase II study is evaluating the effectiveness of a new targeted therapy (RXC004) in people with RNF43 mutation advanced or metastatic pancreatic ductal cancer or biliary tract cancer that have progressed following standard of care treatmentA Modular, Phase II, Open-Label, Multicentre Study to Assess the Preliminary Efficacy and Safety of RXC004, in Patients With Advanced Solid Tumours That Have Progressed Following Therapy With Current Standard of Care

Clinical summary Eligibilty Participating hospital Support

Clinical summary

Summary

This Phase II, modular, open label, multicentre study will initially open with ring finger protein 43 (RNF43) loss of function (LoF) mutation-positive pancreatic ductal adenocarcinoma (PDAC) (Module 1) and biliary tract cancer (BTC) (Module 2) modules. All participants will receive RXC004 (2mg daily, orally). Denosumab will also be administered via subcutaneous injection at a dose of 120mg once a month.

Age

People 18+

Phase

Trial Acronym

PORCUPINE2

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

NCT04907851

Commercial Sponsor

Redx Pharma Plc

Scientific Title

A Modular, Phase II, Open-Label, Multicentre Study to Assess the Preliminary Efficacy and Safety of RXC004, in Patients With Advanced Solid Tumours That Have Progressed Following Therapy With Current Standard of Care

Share with email

Print this page

Download brochure

Eligibility

Inclusion

You have certain types of non-cancer medical conditions.
You have had certain treatments, surgical procedures or drugs.
You have previously been treated (or are currently being treated) on a clinical trial.

Exclusion

You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
Your cancer has not spread to other parts of the body.
Your cancer has spread to other parts of the body.

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

Information Tell us if you find this trial availability is not accurate.Report inaccuracy